TROP2-Directed ADCs Are Redefining TNBC Management

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, review emerging data for TROP2-directed antibody-drug conjugates (ADCs) and their impact on metastatic triple-negative breast cancer (TNBC). The pair highlight key findings from phase 3 trials such as ASCENT-03 (NCT05382299), ASCENT-04 (NCT05382286), and TROPION-Breast02 (NCT05374512) that support the growing role of these agents. They also discuss how these data may position ADC-based regimens as a potential frontline standard for select patients with TNBC.